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Background: Cytoreductive surgery combined with ‘Hyperthermic IntraPEritoneal Chemotherapy’ (HIPEC)
represents the only potentially curative treatment available for carcinomatosis secondary to colorectal cancer (CRC),
pseudomyxoma peritonei (PMP), malignant peritoneal mesothelioma (MM) and goblet cell carcinoma (GCC).
Despite preoperative investigation some patients are excluded perioperatively because of unacceptably massive
tumor extent. The data available on the clinical course of these patients are sparse. The aim of this study was to
investigate mortality, morbidity and clinical course for patients who were excluded.
Methods: This was a retrospective observational study based on records from 35 patients (21 men, 14 women)
treated in a national center (Surgical Department P, Aarhus University Hospital) from June 2006 to August 2011 and
excluded from the cytoreductive surgery perioperatively. The study population included patients aged 18 to 70
years with CRC (n = 19), PMP (n = 11), MM (n = 3) or GCC (n = 2). Vital status was obtained by 29 November 2012.
Three patients were lost to follow-up.
Results: The 30-day mortality rate was 0%. Postoperative complications within 30 days occurred in three patients
(9.4%). In all, 19 patients (54%) had palliative surgery during exploratory laparotomy. In total, 28 patients (88%)
received postoperative palliative chemotherapy. The median survival for CRC and PMP patients was 12.7 (95% CI 4.0
to 21.4) and 26.9 (95% CI 25.7 to 28.1) months, respectively.
Conclusions: Exploratory laparotomy for intended curative treatment of peritoneal carcinomatosis did not imply
major morbidity or mortality for patients excluded from treatment due to advanced stage of disease.
Keywords: Colorectal cancer, Malignant mesothelioma, Goblet cell carcinoid, Pseudomyxoma peritonei, Treatment
outcome, Postoperative complicationsBackground
Peritoneal carcinomatosis (PC) represents the spread of
malignancies to the parietal and visceral peritoneum.
Cytoreductive surgery (CRS) and ‘Hyperthermic IntraPEri-
toneal Chemotherapy’ (HIPEC) was introduced in the early
1990s as a potentially curative treatment in selected pa-
tients including PC secondary to colorectal cancer (CRC)
and other malignancies such as pseudomyxoma peritonei* Correspondence: anne.p.rodt@gmail.com
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reproduction in any medium, provided the or(PMP) malignant peritoneal mesothelioma (MM) and gob-
let cell carcinoid (GCC) [1]. CRS aims to remove all visible
tumor tissue (<2.5 mm). The HIPEC procedure is based on
the principle that a high concentration of cytostatic drugs
can eradicate the non-visible malignant cells in the upper
layers of cells, while systemic absorption, and thereby tox-
icity, is limited. CRS and HIPEC may increase the 5-year
survival up to 51% in selected patients with PC originating
from CRC [2] and 87%-94% in patients with PMP [3,4].
The outcome of CRS and HIPEC depends on the tumor
extent and the completeness of cytoreduction [5]. Selection
of patients is challenging. Some patients deemed amenabled. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cluded from CRS and HIPEC because of an unacceptably
extensive tumor extent or unresectable disease, despite pre-
operative investigation with positron emission tomography-
computed tomography (PET-CT). The literature on the
clinical course for this group of patients is sparse. In this
observational study, we present data on the clinical course
and survival for patients found ineligible for CRS and
HIPEC at time of surgery due to advanced stage PC.
Methods
Patients referred to the Department of Surgery P, Aarhus
University Hospital for suspected or diagnosed PC and
potential need for CRS and HIPEC were registered pro-
spectively from June 2006. The department is a national
referral center for the CRS and HIPEC procedures [6].
Patients eligible for CRS and HIPEC were patients
with PC originating from CRC, PMP, MM or GC. Exclu-
sion criteria were: (1) physiological age above 70 to 75
years, (2) moderate and severe comorbidity as judged by
an American Society of Anesthesiologists (ASA) score
≥III, (3) extraperitoneal disease, (4) invasive growth into
the retroperitoneal space or the abdominal wall (except
disease situated in previous incisions and port sites), (5)
massive disease involvement of the small bowel or its
mesentery, (6) more than one stenosis of the small bowel
because of PC, (7) disease involvement of the hepatic
pedicle or the pancreas, and (8) (for PC from CRC and
appendiceal cancer only) PC extent in six or seven re-
gions as estimated by Dutch 7 Region Count [7].
Preoperative assessment included CT/PET-CT of the
lungs, abdomen and pelvis, and also colonoscopy if this
had not been performed during the last year. From Sep-
tember 2010, diagnostic laparoscopy was also performed
for the vast majority of patients. The overall completion
rate of CRS and HIPEC increased from 56% to 70% after
its introduction [8].
Treatment decisions were finalized in multidisciplinary
team meetings. Final assessment of eligibility was
performed at scheduled CRS and HIPEC during explora-
tive laparotomy procedures, with staging of tumor extent
according to the Dutch 7 Region Count Score [7] and
evaluation of resectability.
From 1 June 2006 to 1 August 2011, 35 patients were
excluded perioperatively from CRS and HIPEC.
In cases of unacceptably massive tumor extent or
unresectable disease at time of scheduled CRS and
HIPEC, standard palliative surgery was performed at the
surgeon’s discretion, including resection or bypass of
small bowel/colon/rectum when imminent obstruction
was found omentectomy in severe intractable malignant
ascites or where it was clinically indicated, and in pa-
tients with MM debulking was performed. When stabi-
lized postoperatively, patients were transferred to theirlocal hospitals. After discharge, these hospitals also re-
ceived patients for readmissions, including secondary
palliative surgery and palliative chemotherapy. Other-
wise, these patients were treated by their general practi-
tioner, public hospices, and by a public home nursing
organization.
Patients were prospectively registered in connection
with exploratory laparotomy including the reason(s) for
perioperative exclusion from CRS and HIPEC. Data
on postoperative complications and reoperations,
readmissions and palliative surgery were collected retro-
spectively as of 15 December 2011 by review from
E-journal, a Danish nationwide digital system of patient
records. Postoperative infections were registered when
verified, sepsis if symptoms and positive blood culture,
wound infection if surgical debridement was needed,
and pneumonia if verified by X-ray. Vital status was
obtained as of 29 November 2012 and postoperative
mortality (≤30 days) and overall survival were calculated.
Total duration of hospitalization was registered for pa-
tients passed away as of 15 December 2011.
Statistical analysis
Data were stratified according to primary diagnosis and
given as median and range. In order to estimate time
spent in hospital relative to residual lifetime after exclu-
sion from CRS and HIPEC, readmission time was regis-
tered in percentage of survival for each patient
succumbed at time for data collection (15 November
2011), and median and range of these data were calcu-
lated. Overall survival from time scheduled CRS and
HIPEC was estimated using the Kaplan-Meier method.
The Mann-Whitney-Wilcoxon test was used to estimate
significance between two medians in the nonnormal small
sample populations. P <0.05 was considered significant.
Results
CRC and PMP constituted approximately one-half and
one-third of patients, respectively (Table 1). The main
reasons for exclusion comprised affection of more than
five of seven peritoneal regions [7] for CRC patients and
widespread PC of the small bowel or the mesentery for
PMP patients (Table 2). About one-half of the patients
presented ≥2 contraindications.
Palliative surgery was performed in 19 patients (54%),
and included omentectomy in 16 patients (40%), resec-
tions of colon or rectum in 7 patients and bypass proce-
dures in 2 patients (Table 3).
Postoperative clinical course
The 30-day postoperative mortality after the exploratory
laparotomy was 0%.
Postoperative complications within 30 days occurred
in three patients (9.4%), who all received at least 2
Table 1 Demographic data for patients excluded perioperatively from CRS and HIPEC (n = 35)
Demographic CRC PMP MM GCC Total
Number of patients (%) 19 (54%) 11 (31%) 3 (9%) 2 (6%) 35 (100%)
Male/female 11/8 7/4 3/0 0/2 21/14
Age in years (median; range) 58 (22; 76) 57 (35; 76) 42 (38; 50) 61 (59; 63) 58 (22; 76)
CRC colorectal cancer, CRS cytoreductive surgery, GCC goblet cell carcinoid, HIPEC hyperthermic intraperitoneal chemotherapy, MM malignant peritoneal
mesothelioma, PMP pseudomyxoma peritonei.
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omentectomy and resection of umbilicus. Patient 2:
Omentectomy, gynocological procedures, small bowel
resection, ileocaecal and rectum resection. Patient: 3
Omentectomy and ileocaecal resection). One patient had
a rectal stump blowout after surgery. This was treated
with drainage by Foley catheter. Another patient had an
infected hematoma in the abdomen evacuated by sur-
gery. A third patient received antibiotics for sepsis. A
total of 11 patients had an anastomosis, 9 resections (in-
cluding small intestines) and 2 bypass procedures; none
of them experienced a leakage.Follow-up
Data on postoperative complications, readmissions and
palliative surgery after discharge were missing for three
patients, because postoperative data was not registered
in E-journal, including two transferred to Greenland.
Median follow-up regarding postoperative complica-
tions, readmission and palliative surgery for CRC pa-
tients were 9 months (range 1 to 36 months), PMP
were 20 months (range 2 to 65 months), MM were 22
months (range 9 to 35 months) and GCC were 20
months (range 17 to 23 months). Vital status was avail-
able for all 35 patients. Follow-up regarding overall sur-
vival was longer with median values of 13 months
(range 1 to 44 months) for CRC, 26 months (range 2
to 66 months) for PMP, 33 months (range 9 to 46
months) for MM, and 26 months (range 18 to 34
months) for GCC.Table 2 Criteria for perioperative exclusion (n = 35)
Criteria CRC (n =19)
Involvement of >5 regions 9 (31%)
Involvement of pancreas 2 (7%)
Involvement of portahepatis 1 (3%)
Stenosis of the ureter(s) 2 (7%)
≥2 bowel stenoses 3 (10%)
Widespread carcinomatosis in bowel/mesentery 5 (17%)
Retroperitoneal involvement 3 (10%)
Othera 4 (14%)
Total number of reasons 29 (100%)
aOther reasons included: liver metastases, para-aortal gland involvement, involveme
CRC colorectal cancer, GCC goblet cell carcinoid, MM malignant peritoneal mesotheSecondary hospitalization
Secondary operative intervention was needed in eight
patients (25%) including three CRC patients, three PMP
patients, and two GCC patients. Six of the eight patients
had bowel obstruction, and decompression palliative
procedures were performed in five. Two patients died
within 30 days after the secondary operation, including
one patient in whom surgery was deemed futile during
operation. Three patients chose to have further surgery
performed abroad (Germany, India and China, all with
palliative outcomes), and were subsequently referred
back to their local hospital in Denmark for postoperative
care for median 24 days (range 14 to 42 days). Medical
data from their hospitalization abroad was not available.
Apart from surgery and chemotherapy, treatment in-
cluded a variety of palliative measures. For many pa-
tients, final terminal care was provided by public
hospices.
A total of 13 (68%) CRC patients and 5 (45%) PMP pa-
tients were deceased at time for follow-up regarding the
postoperative complications. These patients spent 7%
(PMP) to 10% (CRC) of their remaining time in hospital.
Postoperative chemotherapy
In total, 28 patients (88%) subsequently received pallia-
tive chemotherapy according to the Danish national
guidelines [9]. In all, 14 CRC patients (82%) received
chemotherapy (2 CRC patients were lost for follow-up).
The median interval between the exploratory laparotomy
and the initial chemotherapy was 29 days (20; 224). Nine
PMP patients (90%) (one was lost to follow-up) receivedPMP (n =11) MM (n =3) GCC (n = 2)
NA NA 1 (50%)
1 (7%) 1 (14%) 0 (0%)
5 (33%) 2 (29%) 1 (50%)
0 (0.0%) 0 (0%) 0 (0%)
0 (0.0%) 0 (0%) 0 (0%)
8 (53%) 3 (43%) 0 (0%)
0 (0%) 0 (0%) 0 (0%)
1 (7%) 1 (14%) 0 (0%)
15 (100%) 7 (100%) 2 (100%)
nt of urinary bladder, severe adhesions and the stomach.
lioma, PMP pseudomyxoma peritonei.
Table 3 Palliative procedures performed during the exploratory laparotomy procedure (n = 35)
Procedure CRC (n = 19) PMP (n = 11) MM (n = 3) GCC (n = 2)
Omentectomy 6 (38%) 6 (43%) 3 (75%) 1 (20%)
Colon resection 3 (19%) 1 (7%) 0 (0%) 0 (0%)
Splenectomy 0 (0%) 1 (7%) 1 (25%) 0 (0%)
Resection of small bowel 1 (6%) 0 (0%) 0 (0%) 1 (20%)
Ileocecal resection 1 (6%) 3 (21%) 0 (0%) 1 (20%)
Bypass procedure 2 (13%) 0 (0%) 0 (0%) 0 (0%)
Gynecological proceduresa 1 (6%) 0 (0%) 0 (0%) 1 (20%)
Rectal resection 0 (0%) 0 (0%) 0 (0%) 1 (20%)
Other proceduresb 2 (13%) 3 (21%) 0 (0%) 0 (0%)
Total no. of proceduresc 16 (100%) 14 (100%) 4 (100%) 5 (100%)
Total no. (%) of patients who underwent a palliative procedure 9 (47%) 6 (55%) 3 (100%) 1 (50%)
aIncludes hysterectomy and salpingo-oophorectomy.
bOther procedures included: excision of the umbilicus, peritonectomy and operation for the correction of a diaphragmatic hernia.
cIn all, 14 patients had ≥1 procedure performed.
CRC colorectal cancer, GCC goblet cell carcinoid, MM malignant peritoneal mesothelioma, PMP pseudomyxoma peritonei.
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chemotherapy was 37 days (23; 714). All MM and GCC
patients received chemotherapy. For MM the median
interval was 43 days (29; 818) and GCC 29.5 (16; 43).
Initiation of postoperative chemotherapy was delayed in
patients who underwent palliative surgery during ex-
ploratory laparotomy as compared to those who had ex-
plorative laparotomy only. CRC patients who had
explorative laparotomy had their first chemotherapy 28.5
(19;121) days after surgery, whereas CRC patients who
received palliative procedures during explorative laparot-
omy had their first treatment 36.5 (20;224) daysFigure 1 Kaplan-Meier curve for overall survival of patients with perit
pseudomyxoma peritonei.postoperatively. Similarly for PMP patients; 37 (25;714)
days and 48 (23;64) days in those had not and had pallia-
tive procedures. The difference was not significant in ei-
ther group (respectively P=0.66 and P=0.90).
Survival
By 29 November 2012, 12 patients were still alive. Me-
dian survival was 12.7 months (95% CI 4.0 to 21.4) for
CRC patients and 26.9 months (95% CI 25.7 to 28.1) for
PMP patients, respectively (Figure 1). Median survival
for patients with MM was not reached; two patients
were still alive at 32.9 and 45.8 months, respectively,oneal carcinomatosis of colorectal origin and
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GCC patient was alive 33.6 months after surgery and
one passed away after 17.5 months.
Discussion
This study showed a 30-day mortality rate of 0% and post-
operative complications occurred in less than 10% of pa-
tients perioperatively excluded from CRS and HIPEC. In
patients who only had exploratory laparotomy without
palliative surgical intervention, no significant postopera-
tive complications were observed. When implementing
new treatment regimens, it is important to obtain infor-
mation on the group of patients deemed potential candi-
dates for the new treatment, but found ineligible following
invasive investigation procedures, such as exploratory
laparotomy. One might be concerned that the exploratory
laparotomy inflicted unnecessary morbidity and mortality
and affected overall survival and quality of life negatively
compared with traditional treatments.
Patients not fulfilling the eligibility criteria for CRS
and HIPEC represent a group with highly advanced PC.
It might be expected that these patients displayed a
rapid, fatal clinical course, but our results showed a me-
dian survival in the CRC group of 12.7 months. These
findings are comparable to results found by Hompes et
al. who found a median survival of 9.3 months for pa-
tients with PC who received systemic chemotherapy [10]
as did 88% of patients in the current study. The differ-
ence in survival might be explained by the difference in
the number of patients who received chemotherapy.
However, it is more likely to assume the difference in
survival is caused by selection bias since present patients
were potential candidates for CRS and HIPEC, that is,
without massive PC and fit for major surgery. A ran-
domized prospective study by Bloehmendaal et al. [11]
found an overall survival of 12.6 months for 50 patients
with PC of colorectal origin randomized for standard
treatment including simple chemotherapeutic regimens
and not modern combination regimens. These patients
were also highly selected and were therefore more com-
parable to the patients in this study. Present results do
not indicate any reduction in survival of CRC patients
despite an exploratory laparotomy, but our study is of
limited size. Nevertheless, the median survival for CRC
patients with PC as the only manifestation of dissemi-
nated illness is poor.
Data on survival for patients with PMP show marked
variation. Youssef et al. reported that major debulking
including hemicolectomy, omentectomy and splenec-
tomy when needed, resulted in a median survival of 3.0
years (95% CI 2.2 to 3.8), however 29% of the patients
received HIPEC as well and surgical palliative proce-
dures were performed on a larger percentage of patients
[3]. The 26.9 months survival in patients in the currentstudy precluded from CRS and HIPEC is difficult to as-
sess in this context. Furthermore, the classification of
PMP and differentiation between high and low grade
PMP remains a problem and a common understanding
are desirable [12]. Firm data on the optimal treatment of
PMP patients for whom complete cytoreduction is not
possible are needed.
The patients received initial postoperative chemother-
apy between 29 (CRC) and 43 (MM) days after explora-
tory laparotomy. No prospective randomized studies
describing the optimal time interval from operation to
postoperative chemotherapy exist. The current Danish
standard treatment is based on the Multicenter Inter-
national Study of Oxaliplatin/5-Fluorouracil/Leucovorin
in the Adjuvant Treatment of Colon Cancer (MOSAIC)
study [9] and recommends that patients should start
treatment within 7 weeks. In present study, exploratory
laparotomy did not delay the initiating chemotherapy as
all patients fulfilled the MOSAIC requirements. How-
ever, it was noted that patients who underwent palliative
surgery in general started chemotherapy eight (CRC)
and 11 (PMP) days later then the patients who only had
exploratory laparotomy. However this difference was not
significant. One could suggest that the difference in dur-
ation between operation and chemotherapy across pa-
tient groups might be explained by the existence of a
nationally defined cancer package for CRC patients [13].
It is encouraging that deceased patients spent only ap-
proximately 10% of their residual lifetime in hospital, inde-
pendent of tumor origin. These positive figures should be
interpreted in light of the well-developed primary public
health care system comprising general practitioners, pal-
liative teams as well as possibilities for final terminal care
in hospices. The patient population studied was heteroge-
neous due to different underlying diseases. Therefore, we
analyzed data categorized by primary disease making the
groups even smaller. This is especially true for patients
with MM and GCK (three and two patients), both of
which are rare diseases. Therefore, we focussed mainly on
the outcome of CRC and PMP patients.
The collection of data suffered the natural limitations of a
retrospective study. E-journal is a nationwide digital system
of patient records. It was introduced in 2005, but the fre-
quency of reporting still varies between regions and depart-
ments. However, when departments report to E-journal,
then all data from the patient records are reported. Postop-
erative complications may be underreported in the patient
records; however, the registration of overall survival was
not influenced. Patients in the present study include a se-
lected group of PC patients as it was expected that curative
CRS and HIPEC could be performed. Patients with poor
physical condition and massive PC extent had already been
excluded. This could affect the results towards a better
outcome.
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This study showed that exploratory laparotomy prior to
CRS and HIPEC is not associated with considerable
morbidity or mortality for patients being perioperatively
excluded from CRS and HIPEC. Nor do following pallia-
tive surgical procedures appear to be related to sustained
postoperative morbidity and these procedures do not
significantly delay potential postoperative chemotherapy.
Seemingly, overall survival is not reduced despite ex-
ploratory laparotomy.
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